Moderna shares plunge nearly 20% following cancer vaccine data leak
MRNA Moderna Inc
$202.63 -17.57%
View chart & analysis → - 1Moderna shares fell nearly 20% on Thursday, marking the largest decline among S&P 500 losers.
- 2Phase 3 clinical trial results showed a 42% reduction in the risk of recurrence or death when combining Merck's Keytruda with Intismeran.
- 3UBS analysts suggested the market reaction may reflect excessive investor expectations.
So what's the key point?
Moderna's stock price dropped significantly by nearly 20% following the release of cancer vaccine trial results. Experts believe this happened because the results were lower than what investors had expected.
Source Investor's Business Daily +15 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.